The androgen receptor (AR) signaling pathway is critical for growth and differentiation of
prostate cancer cells. For that reason, androgen deprivation therapy with medical or surgical …

The success of next-generation androgen receptor (AR) pathway inhibitors, such as
abiraterone acetate and enzalutamide, in treating prostate cancer has been hampered by …

Therapy resistance is a significant challenge for prostate cancer treatment in clinic. Although
targeted therapies such as androgen deprivation and androgen receptor (AR) inhibition are …

Prostate cancer (PCa) has become the most common form of cancer in men in the
developed world, and it ranks second in cancer-related deaths. Men that succumb to PCa …

Tumours adapt to increasingly potent targeted therapies by transitioning to alternative
lineage states. In prostate cancer, the widespread clinical application of androgen receptor …

Prostate cancer (PC a) is the most common form of cancer in men in the developed world
and the second leading cause of cancer‐related deaths. While advanced PC a is initially …

The use of androgen deprivation therapy and second line anti-androgens in prostate cancer
has led to the emergence of tumors employing multiple androgen receptor (AR)-dependent …

Androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer,
and the development of castrate-resistant prostate cancer (CRPC) is the primary cause of …

Prostate cancer is a highly heterogeneous disease. Progression on androgen deprivation
therapy (ADT) to castration-resistant (CRPC), or neuroendocrine prostate cancer (NEPC), is …

Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay
of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens …